FDA and MHRA Strengthen Transatlantic Regulatory Alignment on AI, Devices, and Medicines

The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) have announced a new formal collaboration initiative designed to deepen regulatory alignment across medical devices, artificial intelligence, and innovative medicines.

The initiative aims to improve the speed and consistency of regulatory decision-making while preserving the independence of both agencies. It reflects a broader effort to keep pace with rapid scientific and technological advances shaping global healthcare development.

A More Structured Model for Regulatory Cooperation

At the centre of the programme is a new liaison framework, with reciprocal officer roles established within both agencies. These dedicated positions are intended to support ongoing scientific exchange, streamline communication, and improve coordination on emerging regulatory challenges.

By embedding collaboration into day-to-day operations, the FDA and MHRA aim to reduce friction for developers operating across both markets, particularly in high-growth areas such as AI-enabled healthcare technologies and next-generation medical devices.

The programme was formally introduced at the DIA Global Annual Meeting in Philadelphia, held from 14 to 18 June.

MHRA CEO Lawrence Tallon said the initiative represents a step change in collaboration between the two regulators, particularly in how they share expertise and respond to technological change.

He noted that improved alignment could help companies bring products to market more efficiently in both the UK and the US, reducing duplication in regulatory processes.

FDA deputy commissioner Grace Graham also emphasised the benefits of closer cooperation, highlighting faster access to medical products and improved regulatory efficiency for patients and innovators.

Industry Welcomes Reduced Friction Across Markets

The announcement has been broadly welcomed by industry stakeholders. Scott Whitaker, CEO of the Advanced Medical Technology Association (AdvaMed), said closer alignment between the agencies could help reduce regulatory burden and accelerate patient access to medical technologies on both sides of the Atlantic.

The initiative also builds on earlier commitments made in April to strengthen UK-US cooperation in medical device regulation.

It comes at a time when governments and regulators are increasingly focused on balancing innovation with safety in fast-moving sectors such as AI-driven diagnostics and software-based medical devices.

Linking Regulatory Alignment to Broader UK-US Policy Shifts

The collaboration follows recent developments in UK-US pharmaceutical policy, including a trade and pricing agreement implemented in April 2026. That deal removed tariffs on UK pharmaceutical exports to the US and adjusted NHS pricing frameworks for new branded medicines.

Commenting on the broader context, Duncan Edwards, CEO of BritishAmerican Business, said the initiative sends a positive signal for cross-border investment and innovation, highlighting the importance of regulatory certainty for industry planning and growth.

Advancing AI Regulation in Healthcare

The MHRA’s involvement in the programme also coincides with its ongoing work to develop a new regulatory framework for artificial intelligence in healthcare.

This framework is expected to replace the UK’s current medical device regulation system as it applies to AI technologies. As part of this process, the MHRA established the National Commission on the Regulation of AI in Healthcare to gather evidence and stakeholder input.

Recent consultation findings, published on 11 June, highlighted strong demand for reform. Of 761 responses from NHS organisations, industry, and academia, half of respondents called for substantial revision of the existing framework, while a further 21% supported a complete overhaul.

A Step Toward Global Regulatory Convergence

The FDA–MHRA liaison programme reflects a wider trend toward international regulatory convergence in healthcare.

As medical technologies become increasingly global in development and deployment, regulators are under growing pressure to coordinate standards, share expertise, and reduce duplication without compromising safety.

While both agencies retain full autonomy in decision-making, the initiative signals a more structured and collaborative approach to managing innovation across borders.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com